Formulation and Evaluation of Famotidine Floating Matrix Tablets - Pharmaceutical Technology

Latest Issue
PharmTech

Latest Issue
PharmTech Europe

Formulation and Evaluation of Famotidine Floating Matrix Tablets
The authors investigated the effects of formulation and processing parameters on floating matrix-controlled drug-delivery systems.


Pharmaceutical Technology
Volume 33, Issue 10, pp. 60-70

Methods


Table II: Evaluation parameter of tablets of all batches.
Tablets preparation. Different tablet formulations of 100 tablets each were prepared using direct compression. All powders were passed though an 80-mesh sieve. The required quantity of drug, matrix polymer (natural and synthetic), and low-density powder were mixed thoroughly. Talc and magnesium stearate were added as a glidant and a lubricant, respectively. Blending was carried out using a laboratory-scale V-blender with a 100-g capacity (modelAP-01, Orchid Scientifics, Nashik, Maharashtra, India) for 30 min. The blend was compressed with a multipunch tablet compressor (lab press, Cadmach Csi 670, India) at dwell times of 20 s and under a pressure of 25 kg/cm2 . Each tablet contained 40 mg of famotidine and other pharmaceutical ingredients (see Table I). The tablets were round and flat with an average diameter of 8.0 ± 0.1 mm, a hardness of 4–6 kg/cm2 , and a thickness of 4.0 ± 0.2 mm. The tablets were evaluated for weight variation, drug content, and floating lag time (see Table II).

Floating behavior. In vitro buoyancy was determined by determining the floating lag time (i.e., the time period between placing the tablet in the medium and the tablet floating) (15). The tablets were placed in a 100-mL beaker containing 0.1 N HCl. The time required for the tablets to rise to the surface and float was defined as the floating lag time.

In vitro dissolution studies. The release rate of famotidine from the floating tablets (n = 3) was determined using United State Pharmacopoeia (USP) XXIV dissolution testing apparatus II (paddle method). The dissolution test was performed using 900 mL of 0.1 N HCl at 37 ± 0.5°C and 50 rpm. A 10-mL sample of the solution was withdrawn from the dissolution apparatus hourly for 8 h, and the samples were replaced with fresh dissolution medium. The samples were filtered through a 45-µm membrane filter and diluted to a suitable concentration with 0.1N HCl. Absorbance of these solutions was measured at 265 nm using a Shimadzu (Kyoto, Japan) UV-1601 UV–vis double-beam spectrophotometer. Cumulative percentage of drug release was calculated using an equation obtained from a standard curve.

Comparison of dissolution profiles. The similarity factor (f 2 ) given by scale-up and postapproval changes (SUPAC) guidelines for modified-release dosage forms was used as a basis to compare dissolution profiles. The dissolution profiles are considered similar when f 2 is between 50 and 100 (16).


ADVERTISEMENT

blog comments powered by Disqus
LCGC E-mail Newsletters

Subscribe: Click to learn more about the newsletter
| Weekly
| Monthly
|Monthly
| Weekly

Survey
How does your company apply quality-by-design (QbD) principles to manufacturing processes?
To all processes for both new and legacy products
To all process for new products only
To select process for new products only
To select processes for both new and legacy products
Do not use QbD
To all processes for both new and legacy products
18%
To all process for new products only
13%
To select process for new products only
22%
To select processes for both new and legacy products
22%
Do not use QbD
24%
View Results
UPCOMING CONFERENCES

Programs for Investigational and Pre-Launch Drugs
Philadelphia, PA
July 17-18, 2013
Request Brochure

Strategic Pipeline Planning & Portfolio Valuation
Philadelphia, PA
August 13-14, 2013
Request Brochure

MES 2013 - Forum on Manufacturing Execution Systems
Philadelphia, PA
August 14-15, 2013
Request Brochure

Mobile Innovation for the Life Sciences Industry
Philadelphia, PA
August 20-21, 2013
Request Brochure

See All Conferences >>

Eric Langer Outsourcing Outlook Eric LangerOutsourcing's Modest Role as a Cost-Containment Strategy
Patricia Van Arnum Ingredients Insider Patricia Van ArnumIntellectual Property Battles in Solid-State Chemistry
Nathan Jessop Industry Insider Nathan Jessop Campaign Against Counterfeit Drugs Continues
Lynn Torbeck Statistical Solutions Lynn D. TorbeckCompositing Samples and the Risk to Product Quality
 More
Inadequate Access to Medicines Puts EU at Risk
FDA Offers Insight on QbD for Modified-Release Products
Global Biosimilars Market to Reach $2.445 Billion in 2013
Adapting to Change
AstraZeneca and Exco InTouch Collaborate to Augment Current COPD Pathways
FindPharma Custom Search
Source: Pharmaceutical Technology,
Click here